0006-5007 NDC - DELSTRIGO (DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE)

Drug Information

Product NDC: 0006-5007

Proprietary Name: DELSTRIGO

Non Proprietary Name: doravirine, lamivudine, and tenofovir disoproxil fumarate

Active Ingredient(s):
  • 100 mg/1 DORAVIRINE;
  • 300 mg/1 LAMIVUDINE;
  • 300 mg/1 TENOFOVIR DISOPROXIL FUMARATE


Administration Route(s): ORAL

Dosage Form(s): TABLET, FILM COATED

Pharmacy Class(es):
  • Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC];
  • Non-Nucleoside Reverse Transcriptase Inhibitors [MoA];
  • Non-Nucleoside Analog [EXT];
  • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC];
  • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC];
  • Nucleoside Analog [EXT];
  • Nucleoside Reverse Transcriptase Inhibitors [MoA];
  • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC];
  • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC];
  • Nucleosides [CS];
  • Nucleoside Reverse Transcriptase Inhibitors [MoA]

Labeler Information

Labeler Name: Merck Sharp & Dohme Corp.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA210807
Marketing Category: NDA
Start Marketing Date:7/20/2018

Package Information

No. Package Code Package Description Billing Unit
10006-5007-0130 TABLET, FILM COATED in 1 BOTTLE (0006-5007-01)EA

NDC Record

Field Name Field Value Definition
PRODUCT NDC0006-5007The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEDELSTRIGOThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEdoravirine, lamivudine, and tenofovir disoproxil fumarateThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMETABLET, FILM COATEDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE7/20/2018This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERNDA210807This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEMerck Sharp & Dohme Corp.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEDORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATEThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH100; 300; 300 
ACTIVE INGRED UNITmg/1; mg/1; mg/1 
PHARM CLASSESHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Non-Nucleoside Analog [EXT],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleosides [CS],Nucleoside Reverse Transcriptase Inhibitors [MoA] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 5/29/2020